Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) — Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that management will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12th 2:15 p.m. ET.

A live audio webcast of the presentation will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. A replay of the webcast will be available for approximately 30 days following the presentation.

About Evelo Biosciences

Evelo Biosciences is a clinical stage biotechnology company developing orally delivered medicines that act on SINTAX™, the small intestinal axis, and to have systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for defined pharmacological properties.

Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn and video.

Contact

Jessica Cotrone, 978-760-5622
[email protected]



Recro Strengthens Business Development Team to Drive Customer Growth and Diversification

Six Recent Hires Provide Broader Coverage and Expanded Capabilities in the Areas of Sales and Marketing

Significant Traction Already Achieved in First Months of 2021

MALVERN, Pa., April 05, 2021 (GLOBE NEWSWIRE) — Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced significant recent progress in strengthening the company’s business development team to support its strategic objective of expanding and diversifying its customer base. In recent months, the company has added six new members to its business development team, including sales representatives for its emerging Clinical Trial Services (CTS) business, as well as regional representatives bolstering the company’s reach in critical life science markets in Northern and Southern California, Boston and the Midwest.

With these additions, Recro’s current business development team is comprised of 11 experienced professionals, led by longtime global sales and marketing executive, William Hirschman. The efforts of the expanded team have already driven considerable growth for Recro’s customer base during the first quarter of 2021, both through the expansion of the scope of work for several current customers, as well as the onboarding of a number of new customers.

“One of the core objectives of Recro as we move through 2021 and beyond is the achievement of meaningful and sustainable growth through the expansion and diversification of our customer base,” said Mr. Hirschman, Recro’s vice president of sales and marketing. “This goal is at the heart of the company’s forward-looking strategy, and the primary driver for our build out of the company’s business development team. I am pleased with the rapid success achieved in this area by this talented team of professionals. In just the first few months of 2021, these individuals have helped successfully drive significant growth in both our core commercial business, as well as our newer clinical trial materials and related services offering. We have great confidence in the team we have assembled and believe they have the talent and commitment to build on this momentum in the years to come.”

About Recro

Recro (NASD: REPH) is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.

In addition to our experience in handling DEA controlled substances and developing and manufacturing modified release oral solid dosage forms, Recro has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 120,000 square feet, in Gainesville, Georgia.

For more information about Recro’s CDMO solutions, visit recrocdmo.com.

Cautionary Statement Regarding Forward Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements, among other things, relate to the Company’s ability to manage costs and to achieve its financial goals; to operate under increased leverage and associated lending covenants; to pay its debt under its credit agreement and to maintain relationships with CDMO commercial partners and develop additional commercial partnerships. The words “anticipate”, “believe”, “could”, “estimate”, “upcoming”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “will” and similar terms and phrases may be used to identify forward-looking statements in this press release. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that could cause the Company’s actual outcomes to differ materially from those expressed in or underlying these forward-looking statements include the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the customer ordering patterns or inventory rebalancing or disruption in raw materials or supply chain; demand for the Company’s services, which depends in part on customers’ research and development and the clinical plans and market success of their products; customers’ changing inventory requirements and manufacturing plans; customers and prospective customers decisions to move forward with the Company’s manufacturing services; the average profitability, or mix, of the products the Company manufactures; the Company’s ability to enhance existing or introduce new services in a timely manner; fluctuations in the costs, availability, and suitability of the components of the products the Company manufactures, including active pharmaceutical ingredients, excipients, purchased components and raw materials, or the Company’s customers facing increasing or new competition. These forward-looking statements should be considered together with the risks and uncertainties that may affect our business and future results presented herein along with those risks and uncertainties discussed in our filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to us, and we assume no obligation to update any forward-looking statements except as required by applicable law.

 

 



Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
[email protected]

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
[email protected]

Ryan D. Lake (CFO)
Recro
(484) 395-2436
[email protected]

Palantir Selected by the National Nuclear Security Administration for 5-year, $89.9M Contract for SAFER Project

Palantir Selected by the National Nuclear Security Administration for 5-year, $89.9M Contract for SAFER Project

DENVER–(BUSINESS WIRE)–Palantir Technologies Inc. (NYSE:PLTR) today announced it had been selected by the National Nuclear Security Administration (NNSA) to provide its Office of Safety, Infrastructure, and Operations with a platform for effective knowledge management and data-driven decision-making in an agreement worth up to $89.9 million for a duration of up to 5 years.

Palantir will serve as the platform for NNSA’s Safety Analytics, Forecasting, and Evaluation Reporting (SAFER) project. SAFER will help the NNSA in their mission to manage nuclear security by allowing it to best allocate its human and financial resources to prioritize safety. This is Palantir’s first contract with the NNSA.

For SAFER, Palantir will configure a common operating picture that will integrate data and allow the NNSA to measure the health of safety programs across the organization and provide timely insights into data. The program will give NNSA staff the ability to track, trend, query, analyze, and visualize safety metrics from different sites across the country. Palantir’s software allows for the integration of data across the enterprise regardless of data type or source system, and its granular security model is uniquely suited for the NNSA to collaborate across its sites securely.

“Our work with NNSA illustrates Palantir’s mission to provide software to the world’s most important institutions in support of their most critical work,” said Palantir USG President Akash Jain. “We are excited to expand our work within the U.S. government and provide the NNSA with a high-tech solution to make the best possible use of its resources in support of the Nation’s nuclear security missions.”

About NNSA

Established by Congress in 2000, NNSA is a semi-autonomous agency within the U.S. Department of Energy responsible for enhancing national security through the military application of nuclear science. NNSA maintains and enhances the safety, security, and effectiveness of the U.S. nuclear weapons stockpile; works to reduce the global danger from weapons of mass destruction; provides the U.S. Navy with safe and militarily effective nuclear propulsion; and responds to nuclear and radiological emergencies in the United States and abroad.

About Palantir Technologies

Palantir Technologies is a software company that builds enterprise data platforms for use by organizations with complex and sensitive data environments. From building safer cars and planes, to discovering new drugs and combating terrorism, Palantir helps customers across the public, private, and nonprofit sectors transform the way they use their data. Additional information is available at https://www.palantir.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding the amount and the terms of the contract and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include our ability to meet the unique needs of our customer; the failure of our platforms to satisfy our customer or perform as desired; the frequency or severity of any software and implementation errors; our platforms’ reliability; and our customer’s ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

Lisa Gordon

[email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Technology Other Defense Contracts Other Technology Software Energy Nuclear Data Management Defense

MEDIA:

Logo
Logo

Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer

BASEL, Switzerland, April 05, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Lauren Merendino as Chief Commercial Officer of Myovant Sciences, Inc., effective April 5, 2021. Ms. Merendino brings over 20 years of pharmaceutical and biotech leadership experience to Myovant, with expertise in building and leading commercial teams accompanied by a record of successful product launches. She most recently served as Vice President, Neurological Rare Diseases at Genentech. Ms. Merendino will be a member of Myovant’s Executive Committee, reporting directly to Chief Executive Officer David Marek.

“We are thrilled to welcome Lauren, who joins Myovant at a pivotal point following our transition into a commercial-stage company,” said Mr. Marek. “The recent FDA approval in advanced prostate cancer and our upcoming regulatory milestones in uterine fibroids and endometriosis set us up for an exciting path forward. Lauren’s experience of building and leading top-performing commercial teams will be critical in enabling our therapies to reach patients who can benefit the most. I also want to sincerely thank Adele Gulfo for serving as the interim Chief Commercial Officer over the past year and for her continued support as a member of Myovant’s Board of Directors.”

Ms. Merendino is a seasoned commercial leader with experience across multiple therapeutic areas, including oncology and rare diseases, and across all stages of the product lifecycle. She has played a leadership role in multiple launches, with particular experience in oral therapies and buy-and-bill processes. In her most recent role as Vice President, Neurological Rare Diseases at Genentech, she led the cross-functional team including marketing, sales, market access, medical affairs, and government affairs, overseeing two brands, including the launch of a new treatment for spinal muscular atrophy. Over her tenure at Roche and Genentech, she held a variety of leadership positions spanning national sales, marketing, as well as commercial strategies for molecules in early development and business development deals.

“I am delighted to join Myovant and its highly talented team at this exciting moment in the company’s growth,” said Ms. Merendino. “I believe Myovant has a real opportunity to improve the lives of many women and men, not only with the medicines it is developing but also with its broader commitment to empowering women and men to be active participants in their care journeys.”

About Myovant Sciences 

Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. We have one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Our lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact:

Ryan Crowe
Vice President, Investor Relations
Myovant Sciences, Inc.
+1 (650) 781-9106
[email protected]

Media Contact:

Albert Liao 
Director, Corporate Communications
Myovant Sciences, Inc.
+1 (650) 410-3055
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/998fbf55-69c4-4e0b-a79a-aaef43103621

 



Taylor Morrison First Quarter 2021 Earnings Release Conference Call and Webcast Scheduled

PR Newswire

SCOTTSDALE, Ariz., April 5, 2021 /PRNewswire/ — Taylor Morrison Home Corporation (“Taylor Morrison“), the nation’s fifth largest homebuilder, announced today that it will release its first quarter 2021 results before the market opens on Thursday, April 29, 2021. Taylor Morrison will hold a conference call to discuss its first quarter results the same day, at 8:30 a.m. ET.

A live audio webcast, as well as an archive of the conference call, will be available on Taylor Morrison’s website at investors.taylormorrison.com.

For call participants, the dial-in number is: 1 (855) 470-8731 or 1 (661) 378-9962 and the audience passcode is: 4452459. This call will be recorded and available for replay at investors.taylormorrison.com.

Taylor Morrison’s filings will be available at investors.taylormorrison.com or with the SEC at sec.gov.

About Taylor Morrison

Taylor Morrison Home Corporation (NYSE: TMHC) is the nation’s fifth largest homebuilder and developer based in Scottsdale, Arizona, that has been recognized as America’s Most Trusted® Home Builder for six years running (2016-2021). Operating under a family of brands including Taylor Morrison, Darling Homes, William Lyon Signature Home and Christopher Todd Communities built by Taylor Morrison, we serve consumer groups coast to coast, from first-time to move-up, luxury and 55-plus buyers. Our unwavering pledge to sustainability, our communities and our team—outlined in the 2019 Environmental, Social and Governance Report—extends to designing thoughtful living experiences homeowners can be proud of for generations to come.

For more information about Taylor Morrison, please visit www.taylormorrison.com.

CONTACT:    
Investor Relations
Taylor Morrison Home Corp.
(480) 734-2060
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/taylor-morrison-first-quarter-2021-earnings-release-conference-call-and-webcast-scheduled-301261788.html

SOURCE Taylor Morrison

Sempra Energy Announces Agreement To Sell Non-Controlling Interest In Sempra Infrastructure Partners

– Announcing agreement to sell 20% equity interest in Sempra Infrastructure Partners to KKR for $3.37 billion

– Simplifying and improving scale of infrastructure business

– Using proceeds to help fund growth of U.S. utilities and further strengthen Sempra Energy’s balance sheet

– Highlighting the value of infrastructure business with expected earnings accretion

PR Newswire

SAN DIEGO, April 5, 2021 /PRNewswire/ — Sempra Energy (NYSE: SRE) today announced that it has entered into a definitive agreement to sell a non-controlling, 20% interest in Sempra Energy’s new business platform, Sempra Infrastructure Partners, to KKR for $3.37 billion in cash. KKR is a leading global investment firm.

This transaction values Sempra Infrastructure Partners at approximately $25.2 billion, including expected asset-related debt at closing of $8.37 billion.

Today’s announcement is part of a series of integrated transactions originally announced in December 2020 that are intended to simplify Sempra Energy’s non-utility infrastructure investments under one self-funding platform, combining the strengths of Sempra LNG, a leading developer of liquefied natural gas (LNG) export infrastructure, and IEnova (Infraestructura Energética Nova, S.A.B de C.V.), one of the largest private energy companies in Mexico and a leading developer and operator of renewables and natural gas infrastructure in that country. This new platform is expected to create scale, unlock portfolio synergies, highlight value and better position the business for growth.

“Over the next decade, we expect the energy markets in North America to continue to grow and become increasingly integrated. Combining our resources with KKR improves our ability to capture new investment opportunities in cleaner forms of energy and the critical infrastructure that stores and transports it,” said Jeffrey W. Martin, chairman and CEO of Sempra Energy. “This transaction also sends a clear signal about the value and expected growth of our infrastructure portfolio.”

“Investing in critical new energy infrastructure creates jobs, delivers reliable energy with fewer emissions and supports North America’s economic recovery,” said Raj Agrawal, KKR Partner and Global Head of Infrastructure. “That is why we are excited to partner with Sempra Energy. This infrastructure platform provides a strong foundation to expand cleaner energy resources across the continent. Backed by strong, contractually-supported, long-term cash flows, our investment is also consistent with KKR Infrastructure’s strategy to seek stable and predictable returns for our investors.”

KKR will be making the investment through its Global Infrastructure Investors Funds. KKR first established its Global Infrastructure strategy in 2008 and has since been one of the most active infrastructure investors around the world with a team of more than 50 dedicated investment professionals. The firm currently has over $27 billion in infrastructure assets under management and has made over 40 infrastructure investments across a range of sub-sectors and geographies.

The transaction is expected to be completed by mid-2021, subject to customary closing conditions, including consents from certain third parties and regulators.

Highlighting Value
Sempra Energy will receive cash proceeds from KKR at the closing of the transaction, subject to certain customary purchase price adjustments, including changes to account for any IEnova shares not tendered in Sempra Energy’s previously announced stock-for-stock exchange offer for the publicly-traded shares of IEnova.

Under the terms of the agreement, KKR will be acquiring its indirect interest in IEnova at $4.13 per share, the price calculated using the proposed exchange ratio announced by Sempra Energy on December 2, 2020 and the closing price of Sempra Energy common stock on April 1, 2021, the last trading day immediately preceding the date of the agreement. KKR will have certain minority rights with respect to Sempra Infrastructure Partners commensurate with the size of its investment.

The new business platform is expected to create increased shareholder value and support the global energy transition by providing an improved platform for innovation and potential new investments in renewables, hydrogen, ammonia, energy storage and carbon sequestration. Sempra Infrastructure Partners owns, among other assets:

  • An LNG portfolio consisting of up to 45 million tonnes per annum (Mtpa) of LNG export capacity in development, construction or operation on the North American Pacific and Gulf Coasts;
  • A renewable portfolio consisting of up to 4 gigawatts (GW) of renewable energy generation in development, construction or operation in Mexico and related electric transmission infrastructure; and
  • A natural gas infrastructure portfolio consisting of distribution companies and certain cross-border and in-country pipelines, including those that export U.S. natural gas to Mexico and supply the Energía Costa Azul LNG facility.

Proceeds from the sale will be used to help fund growth across Sempra Energy’s $32 billion capital program, which is centered on its U.S. utilities, and to further strengthen its balance sheet. The sale is expected to be accretive to earnings.

Also, in December 2020, Sempra Energy announced its intention to launch a stock-for-stock exchange offer for the publicly-traded shares of IEnova, with Sempra Energy’s common shares to be listed on the Mexican stock exchange (Bolsa Mexicana de Valores, S.A.B de C.V.). Sempra Energy intends to commence this exchange offer following approval by the U.S. and Mexican regulatory authorities.

Goldman Sachs & Co. LLC is serving as financial advisor and White & Case LLP is serving as legal advisor to Sempra Energy on this transaction. Credit Suisse Securities (USA) LLC and Mizuho Securities USA LLC are serving as financial advisors and Simpson Thacher & Bartlett LLP and Creel, García-Cuéllar, Aiza y Enríquez, S.C. are serving as legal advisors to KKR.

About Sempra Energy
Sempra Energy’s mission is to be North America’s premier energy infrastructure company. The Sempra Energy family of companies have more than 19,000 talented employees who deliver energy with purpose to over 36 million consumers. With more than $66 billion in total assets at the end of 2020, the San Diego-based company is the owner of one of the largest energy networks in North America serving some of the world’s leading economies. The company is helping to advance the global energy transition by enabling the delivery of lower-carbon energy solutions in each market it serves, including California, Texas, Mexico and the LNG export market. Sempra Energy is consistently recognized as a leader in sustainable business practices and for its long-standing commitment to building a high-performing culture including safety and diversity and inclusion. Sempra Energy is the only North American utility sector company included on the Dow Jones Sustainability World Index and was also named one of the “World’s Most Admired Companies” for 2021 by Fortune Magazine. For additional information about Sempra Energy, please visit Sempra Energy’s website at www.sempra.com and on Twitter @SempraEnergy.

About KKR
KKR is a leading global investment firm that offers alternative asset management and capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of The Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.


Additional Information and Where to Find It

The proposed stock-for-stock exchange offer will be submitted to shareholders of Infraestructura Energética Nova, S.A.B. de C.V. (IEnova) for their consideration. In connection with the proposed exchange offer, Sempra Energy has filed a registration statement with the U.S. Securities and Exchange Commission (SEC), which includes a prospectus relating to the offer and sale of the Sempra Energy common stock to be issued in the exchange offer, and has filed a prospectus and registration statement offering memorandum with the Mexican National Banking and Securities Commission (Comisión Nacional Bancaria y de Valores) (CNBV). Shareholders are urged to read the registration statements carefully and in their entirety, along with any other relevant documents or materials filed or to be filed with the SEC or the CNBV in connection with the proposed exchange offer or incorporated by reference in the registration statements, because they contain important information about the proposed exchange offer and the parties thereto. The registration statements and other documents are available free of charge at the SEC’s internet website, www.sec.gov, and on the CNBV’s website at www.gob.mx/cnbv. The registration statements and other pertinent documents may also be obtained free of charge by directing a written request to Sempra Energy, Attn: Corporate Secretary, at 488 8th Avenue, San Diego, California 92101.

Neither this press release nor the information contained herein shall constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in the United States or Mexico will be made except pursuant to an effective registration statement and by means of the prospectus included in such registration statement and the related materials filed with the SEC and the CNBV. The securities discussed herein will not be offered or acquired until the CNBV has authorized the proposed exchange offer, as provided for in the Mexican Securities Act (Ley del Mercado de Valores), and the SEC has declared effective the registration statement related to the proposed exchange offer that has been filed.


Certain Information Concerning Participants

Sempra Energy and its directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of tenders of securities in connection with the proposed exchange offer. Information about Sempra Energy’s directors and executive officers is included or incorporated by reference in its Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on February 25, 2021.


Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on assumptions with respect to the future, involve risks and uncertainties, and are not guarantees. Future results may differ materially from those expressed in any forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this press release. We assume no obligation to update or revise any forward-looking statement as a result of new information, future events or other factors.

Forward-looking statements in this press release include any statements regarding the ability to complete the proposed transactions described herein on the anticipated timeline or at all, the anticipated benefits of these transactions if completed, the projected impact of these transactions on Sempra Energy’s performance or opportunities, and any other statements regarding Sempra Energy’s expectations, beliefs, plans, objectives or prospects or future performance or financial condition as a result of or in connection with these transactions. In this press release, forward-looking statements can be identified by words such as “believes,” “expects,” “anticipates,” “plans,” “estimates,” “projects,” “forecasts,” “should,” “could,” “would,” “will,” “confident,” “may,” “can,” “potential,” “possible,” “proposed,” “in process,” “under construction,” “in development,” “target,” “outlook,” “maintain,” “continue,” or similar expressions, or when we discuss our guidance, priorities, strategy, goals, vision, mission, opportunities, projections, intentions or expectations.

Factors, among others, that could cause our actual results and future actions to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: the timing of the proposed transactions described herein; the ability to satisfy the conditions to closing these transactions; the ability to obtain regulatory approvals necessary to complete these transactions; the ability to achieve the anticipated benefits of these transactions; the effect of this communication on Sempra Energy’s or IEnova’s stock prices; transaction costs; the diversion of management time on transaction-related issues; the effects on these transactions of industry, market, economic, political or regulatory conditions outside of Sempra Energy’s control; the effects on these transactions of disruptions to Sempra Energy’s or IEnova’s respective businesses; California wildfires, including the risks that we may be found liable for damages regardless of fault and that we may not be able to recover costs from insurance, the wildfire fund established by California Assembly Bill 1054 or in rates from customers; decisions, investigations, regulations, issuances or revocations of permits and other authorizations, renewals of franchises, and other actions by (i) the Comisión Federal de Electricidad, California Public Utilities Commission (CPUC), U.S. Department of Energy, Public Utility Commission of Texas, and other regulatory and governmental bodies and (ii) states, counties, cities and other jurisdictions in the U.S., Mexico and other countries in which we do business; the success of business development efforts, construction projects and major acquisitions and divestitures, including risks in (i) the ability to make a final investment decision, (ii) completing construction projects or other transactions on schedule and budget, (iii) the ability to realize anticipated benefits from any of these efforts if completed, and (iv) obtaining the consent of partners or other third parties; the resolution of civil and criminal litigation, regulatory inquiries, investigations and proceedings, and arbitrations, including, among others, those related to the natural gas leak at Southern California Gas Company’s (SoCalGas) Aliso Canyon natural gas storage facility; the impact of the COVID-19 pandemic on our capital projects, regulatory approval processes, supply chain, liquidity and execution of operations; actions by credit rating agencies to downgrade our credit ratings or to place those ratings on negative outlook and our ability to borrow on favorable terms and meet our substantial debt service obligations; moves to reduce or eliminate reliance on natural gas and the impact of volatility of oil prices on our businesses and development projects; weather, natural disasters, pandemics, accidents, equipment failures, explosions, acts of terrorism, computer system outages and other events that disrupt our operations, damage our facilities and systems, cause the release of harmful materials, cause fires and subject us to liability for property damage or personal injuries, fines and penalties, some of which may not be covered by insurance (including costs in excess of applicable policy limits), may be disputed by insurers or may otherwise not be recoverable through regulatory mechanisms or may impact our ability to obtain satisfactory levels of affordable insurance; the availability of electric power and natural gas and natural gas storage capacity, including disruptions caused by failures in the transmission grid, limitations on the withdrawal of natural gas from storage facilities, and equipment failures; cybersecurity threats to the energy grid, storage and pipeline infrastructure, the information and systems used to operate our businesses, and the confidentiality of our proprietary information and the personal information of our customers and employees; expropriation of assets, failure of foreign governments and state-owned entities to honor their contracts, and property disputes; the impact at San Diego Gas & Electric Company (SDG&E) on competitive customer rates and reliability due to the growth in distributed and local power generation, including from departing retail load resulting from customers transferring to Direct Access and Community Choice Aggregation, and the risk of nonrecovery for stranded assets and contractual obligations; Oncor Electric Delivery Company LLC’s (Oncor) ability to eliminate or reduce its quarterly dividends due to regulatory and governance requirements and commitments, including by actions of Oncor’s independent directors or a minority member director; volatility in foreign currency exchange and interest and inflation rates and commodity prices and our ability to effectively hedge these risks; changes in tax and trade policies, laws and regulations, including tariffs and revisions to international trade agreements that may increase our costs, reduce our competitiveness, or impair our ability to resolve trade disputes; and other uncertainties, some of which may be difficult to predict and are beyond our control.

These risks and uncertainties are further discussed in the reports that Sempra Energy has filed with the SEC. These reports are available through the EDGAR system free-of-charge on the SEC’s website, www.sec.gov, and on the company’s website, www.sempra.com. Investors should not rely unduly on any forward-looking statements.

Sempra North American Infrastructure, Sempra LNG, Sempra Mexico, Sempra Texas Utilities, Oncor and IEnova are not the same companies as the California utilities, SDG&E or Southern California Gas Company, and Sempra North American Infrastructure, Sempra LNG, Sempra Mexico, Sempra Texas Utilities, Oncor and IEnova are not regulated by the CPUC.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/sempra-energy-announces-agreement-to-sell-non-controlling-interest-in-sempra-infrastructure-partners-301261798.html

SOURCE Sempra Energy

NFI confirms BVG order for 198 ADL Enviro500 double deck buses for Berlin

LARBERT, Scotland, April 05, 2021 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF) NFI Group Inc. (“NFI”), one of the world’s leading independent global bus manufacturers, today announced that Berliner Verkehrsbetriebe (“BVG”) has exercised options for 198 Enviro500 double deck buses, to be delivered to the German capital by the end of 2022. Alexander Dennis Limited (“ADL”), a subsidiary of NFI, will build these buses in its factories in the United Kingdom.

NFI delivered the first two Enviro500 double deck buses to BVG in October 2020 as part of a multi-year framework contract signed in 2018. Following the successful completion of a testing programme with this initial pair of vehicles, BVG’s supervisory board approved the conversion of options for another 198 buses into firm orders, taking the fleet to 200. Options for an additional 230 Enviro500 double deck buses remain in the contract.

“This fantastic news is a testament to the incredible efforts of our talented international team at ADL who have yet again demonstrated that they can expand into new markets and deliver for customers in multiple jurisdictions through their ability to execute on highly complex product development projects,” said Paul Soubry, President & Chief Executive Officer, NFI. “We are extremely proud to support a world-class operator in BVG and take a significant step in NFI’s global growth strategy.”

Production of all 198 units will take place at ADL’s facilities in the United Kingdom, with the Scarborough site in Yorkshire to lead final assembly. Once delivered, they will be supported locally by an experienced team operating out of ADL’s recently opened Berlin office, service workshop and parts warehouse.

NFI is a leader and innovator in zero-emission mobility. The Company’s battery-electric and fuel-cell electric vehicles are in more than 80 cities in four countries and have completed over 20 million electric service miles. NFI has the broadest offering of electric vehicles including medium- and heavy-duty transit buses, motor coaches and double-deck buses. NFI subsidiary ADL is the UK’s largest bus manufacturer and continues to lead the evolution to zero-emission mobility with sustainable single-deck buses, double-deck buses, and coaches.

About NFI

Leveraging 450 years of combined experience, NFI is leading the electrification of mass mobility around the world. With zero-emission buses and coaches, infrastructure, and technology, NFI meets today’s urban demands for scalable smart mobility solutions. Together, NFI is enabling more livable cities through connected, clean, and sustainable transportation.

With 8,000 team members in ten countries, NFI is a leading global bus manufacturer of mass mobility solutions under the brands New Flyer® (heavy-duty transit buses), MCI® (motor coaches), Alexander Dennis Limited (single and double-deck buses), Plaxton (motor coaches), ARBOC® (low-floor cutaway and medium-duty buses), and NFI Parts™. NFI currently offers the widest range of sustainable drive systems available, including zero-emission electric (trolley, battery, and fuel cell), natural gas, electric hybrid, and clean diesel. In total, NFI supports its installed base of over 105,000 buses and coaches around the world. NFI common shares are traded on the Toronto Stock Exchange under the symbol NFI. News and information is available at www.nfigroup.com, www.newflyer.com, www.mcicoach.com, www.alexander-dennis.com, www.arbocsv.com, and www.nfi.parts.

About Alexander Dennis

Alexander Dennis Limited (“ADL”) is a global leader in the design and manufacture of double deck buses and is also the UK’s largest bus and coach manufacturer. ADL offers single and double deck vehicles under the brands of Alexander Dennis and Plaxton, and has over 31,000 vehicles in service in the UK, Europe, Hong Kong, Singapore, New Zealand, Mexico, Canada and the United States. Further information is available at www.alexander-dennis.com.

For ADL media inquiries, please contact:
Jacqueline Anderson
+44 7796 715 607
[email protected]

For investor inquiries, please contact:
Stephen King
204.224.6382
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6eeb9b87-2a77-4cfb-acc5-34a6602aabad



Fluor Announces $40 Million Investment in NuScale Power by JGC Holdings Corporation

Fluor Announces $40 Million Investment in NuScale Power by JGC Holdings Corporation

IRVING, Texas–(BUSINESS WIRE)–Fluor Corporation (NYSE: FLR) announced today that JGC Holdings Corporation of Japan invested $40 million into NuScale Power LLC, a leading small modular nuclear reactor (SMR) technology company in which Fluor is the majority investor. In addition to JGC’s ownership interest, JGC will become a global strategic engineering, procurement and construction (EPC) partner for new SMR projects.

“This new ownership stake and partnership with JGC is aligned with Fluor’s long-term strategy to bring aboard new strategic investors to NuScale as the U.S. and international demand for new carbon-free base-load energy grows,” said Alan Boeckmann, executive chairman, Fluor Corporation. “Fluor has been collaboratively executing projects with JGC for more than 10 years and we believe JGC is an ideal partner for effectively bringing this innovative carbon-free energy transition solution to realization.”

Fluor and NuScale are currently working for Utah Associated Municipal Power Systems (UAMPS) to bring the world’s first carbon-free SMR project to commercialization.

In addition to previously announced strategic partners and investors in NuScale, both Fluor and NuScale continue to engage with potential customers, capital investors, manufacturers and other supply chain partners for NuScale SMR deployment efforts.

Fluor has been serving the nuclear industry for more than 70 years including the design and construction support for more than 25 nuclear plants, plus nearly 100 million hours of nuclear operations and maintenance work.

About JGC Holdings Corporation

JGC Holdings Corporation is a holding company comprising world-leading EPC contractor group companies as well as functional materials manufacturing companies. JGC Corporation, its main subsidiary, is an overseas EPC contractor committed to delivering a complete range of project services to our clients, while providing safe and cost-effective project execution. Since its founding in 1928, the JGC Group has executed some 20,000 projects of all sizes across the globe for the oil refining, LNG, petrochemical, power, nuclear, pharmaceutical, and mining industries.

About Fluor Corporation

Fluor Corporation (NYSE: FLR) is building a better future by applying world-class expertise to solve its clients’ greatest challenges. Fluor’s 44,000 employees provide professional and technical solutions that deliver safe, well-executed, capital-efficient projects to clients around the world. Fluor had revenue of $15.7 billion in 2020 and is ranked 181 among the Fortune 500 companies. With headquarters in Irving, Texas, Fluor has provided engineering, procurement and construction services for more than 100 years. For more information, please visit www.fluor.com or follow Fluor on Twitter, LinkedIn, Facebook and YouTube.

Brian Mershon

Media Relations

469.398.7621

Jason Landkamer

Investor Relations

469.398.7222

KEYWORDS: United States Japan North America Asia Pacific Utah Texas

INDUSTRY KEYWORDS: Other Energy Utilities Nuclear Alternative Energy White House/Federal Government Energy Other Construction & Property State/Local Construction & Property Engineering Manufacturing Public Policy/Government

MEDIA:

Logo
Logo

David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund

David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund

NEW YORK–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq: ISEE) today announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bio’s 2021 Annual Stockholder Meeting scheduled to be held on May 19, 2021. Dr. Guyer has served as the Chairman of Iveric’s Board of Directors since its founding. During Dr. Guyer’s tenure he led the Company from its initial public offering to being a late-stage clinical company focused on the discovery and development of both therapeutic and gene therapy treatment options for retinal diseases. Dr. Guyer will rejoin SV Health Investors as a Venture Partner having previously been both a Venture Partner and Partner at SV.

“As a co-founder, former Chief Executive Officer and most recently Executive Chair, David has been an integral part of Iveric Bio’s leadership, a trusted advisor and visionary in retinal medicine, and I sincerely thank him for his hard work and significant contributions to the Company,” stated Glenn P. Sblendorio, Chief Executive Officer and President of Iveric Bio. “On behalf of the entire Company, we are grateful to have had the opportunity to work closely with David over the years and we wish him continued success.”

“Iveric Bio’s strong management team has evolved to the point where there is no longer a need for an Executive Chair,” stated Dr. Guyer. “After more than 14 years on the Board, I feel that this is a good departure point such that I can return to my passion as a venture capitalist. I will rejoin SV Health Investors where I will be able to focus on new company generation and board service. I am very excited about Iveric’s Phase 3 program of Zimura® for the treatment of geographic atrophy secondary to age-related macular degeneration and look forward to continuing to serve the Company as a Senior Advisor.”

“David’s contributions to Iveric Bio have been significant,” stated Axel Bolte, Member of the Board of Iveric Bio. “After having worked with David throughout most of his tenure with the Company, it will be hard to imagine board meetings without David’s presence and clinical insights. We are grateful that David agreed to the Board’s request that he serve as a senior advisor so that we can continue to work with him even if in a different role.”

About Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company, please visit www.ivericbio.com.

Forward-looking Statements

Any statements in this press release about the Company’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company’s strategy, future operations and future expectations and plans and prospects for the Company, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “seek,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. In this press release, the Company’s forward looking statements include statements about the future development of its product candidates and Dr. Guyer’s future role as senior advisor to the Company. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and the progress of research and development programs and clinical trials, availability of data from these programs, reliance on university collaborators and other third parties, establishment of manufacturing capabilities, expectations for regulatory matters, need for additional financing and negotiation and consummation of business development transactions and other factors discussed in the “Risk Factors” section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company’s views only as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law.

ISEE-G

Investor / Media Contact:

Iveric Bio

Kathy Galante, 212-845-8231

Vice President, Investor Relations and Corporate Communications

[email protected]

Media Contact:

SmithSolve

Alex Van Rees, 973-442-1555 ext. 111

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Science Other Science Biotechnology Research Pharmaceutical Optical Health Clinical Trials

MEDIA:

Logo
Logo

STORE Capital to Participate in the Morgan Stanley Triple Net REIT Day

STORE Capital to Participate in the Morgan Stanley Triple Net REIT Day

SCOTTSDALE, Ariz.–(BUSINESS WIRE)–STORE Capital Corporation (NYSE: STOR), an internally managed net-lease real estate investment trust (REIT) that invests in Single Tenant Operational Real Estate, today announced that its management will participate in the Morgan Stanley Triple Net REIT Day being held virtually April 8, 2021. Management will be meeting with investors throughout the conference.

About STORE Capital

STORE Capital Corporation is an internally managed net-lease real estate investment trust, or REIT, that is the leader in the acquisition, investment and management of Single Tenant Operational Real Estate, which is its target market and the inspiration for its name. STORE Capital is one of the largest and fastest growing net-lease REITs and owns a large, well-diversified portfolio that consists of investments in more than 2,600 property locations across the United States, substantially all of which are profit centers. Additional information about STORE Capital can be found on its website at www.storecapital.com.

Financial Profiles, Inc.

[email protected]

Investors or Media:

Moira Conlon, 310-622-8220

Lisa Mueller, 310-622-8231

KEYWORDS: United States North America Arizona

INDUSTRY KEYWORDS: Residential Building & Real Estate Construction & Property REIT

MEDIA:

Logo
Logo